Company: MBIO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001104659-25-009408
Chunk: 91

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 91
---
 the discretion of our board of directors and will depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant.

<div align='center'>59</div>

CAPITALIZATION The following table sets forth our capitalization as of September 30, 2024 as follows:

| ● | on an actual basis; |

| ● | on a pro forma basis to give effect to (i) the issuance of 337,552 shares of common stock in connection with an induced warrant exercise completed in October 2024 and (ii) the issuance of 141,606 shares of common stock in connection with our “at the market” (“ATM”) program; and |

| ● | on a pro forma as adjusted basis to give effect to (i) the pro forma adjustments described above and (ii) the issuance and sale by us of  up to 2,203,856 shares of common stock or, in lieu thereof, pre-funded warrants to purchase up to 2,203,856 shares of common stock, and accompanying Series C-1 Warrants to purchase up to 2,203,856 shares of common stock and Series C-2 Warrants to purchase up to 2,203,856 shares of common stock at an assumed public offering price of $3.63 per share, which is equal to the last reported sale price of our common stock on the Nasdaq Capital Market on February 4, 2025, and after deducting Placement Agent fees and estimated offering expenses payable by us, and assuming exercise in full of any pre-funded warrants offered in this offering, no exercise of the Warrants being offered in this offering, that no value is attributed to such Warrants and that such Warrants are classified as and accounted for as equity. |

You should read this table together with “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as our financial statements and related notes and the other financial information appearing elsewhere in this prospectus. The information presented in the capitalization table has been adjusted to reflect the effect of this current offering.

| ​                                                                                                                                                          
 ​                                                                                                                                                          | ​ 
 ​ | ​                  
 September 30, 2024 |          | ​ | ​         |        ​ | ​ | ​            |        ​ | ​ 
 ​ |
|:-----------------------------------------------------------------------------------------------------------------------------------------------------------|:--|:-------------------|---------:|:--|:----------|---------